These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33981163)

  • 1. MiR-139-5p Targetedly Regulates YAF2 and Mediates the AKT/P38 MAPK Signaling Pathway to Alleviate the Metastasis of Non-Small Cell Lung Cancer Cells and Their Resistance Against Cisplatin.
    Yan Y; Jin X; Sun H; Pang S; Kong X; Bu J; Xu S
    Cancer Manag Res; 2021; 13():3639-3650. PubMed ID: 33981163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of ZNF205-AS1/EGR4 positive feedback loop attenuates cisplatin resistance of non-small cell lung cancer cells via targeting miR-138-5p/OCT4 pathway.
    Li H; Jin Y; Zhu Y; Shen B; Xu Y
    J Thorac Dis; 2024 Jan; 16(1):296-310. PubMed ID: 38410545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell lung cancer by regulating miR-140-5p/Wnt/β-catenin pathway.
    Shi SL; Zhang ZH
    Neoplasma; 2019 Sep; 66(5):756-765. PubMed ID: 31288529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p.
    Li C; Chen L; Song W; Peng B; Zhu J; Fang L
    Acta Histochem; 2021 Oct; 123(7):151788. PubMed ID: 34543777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis.
    Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
    J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of Long Non-Coding RNA
    Zhan Y; Abuduwaili K; Wang X; Shen Y; Nuerlan S; Liu C
    Cancer Manag Res; 2020; 12():7725-7737. PubMed ID: 32943921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis.
    Wang P; Chen D; Ma H; Li Y
    Onco Targets Ther; 2017; 10():5137-5149. PubMed ID: 29123412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salidroside alleviates severe acute pancreatitis-triggered pancreatic injury and inflammation by regulating miR-217-5p/YAF2 axis.
    Wang X; Qian J; Meng Y; Wang P; Cheng R; Zhou G; Zhu S; Liu C
    Int Immunopharmacol; 2022 Oct; 111():109123. PubMed ID: 35963157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mitigates cisplatin resistance in non-small cell lung cancer by mediating the effects of resistant cell-derived exosome mir-424-5p.
    Deng Y; Ding H; Zhang Y; Feng X; Ye Q; Tian R; Xu Y; He Q; Fu Q; Li R
    Heliyon; 2024 Mar; 10(5):e26853. PubMed ID: 38439876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the
    Wang H; Sui ZL; Wu XX; Tang P; Zhang HD; Yu ZT
    Pharmgenomics Pers Med; 2021; 14():497-508. PubMed ID: 33953601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway.
    Xu X; Tao R; Sun L; Ji X
    Cancer Cell Int; 2020 Nov; 20(1):552. PubMed ID: 33292236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. circHUWE1 Exerts an Oncogenic Role in Inducing DDP-Resistant NSCLC Progression Depending on the Regulation of miR-34a-5p/TNFAIP8.
    Yang X; Sun Q; Song Y; Li W
    Int J Genomics; 2021; 2021():3997045. PubMed ID: 34901263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long non-coding RNA PVT1/miR-145-5p/ITGB8 axis regulates cell proliferation, apoptosis, migration and invasion in non-small cell lung cancer cells.
    Wei CM; Zhao XF; Qiu HB; Ming Z; Liu K; Yan J
    Neoplasma; 2020 Jul; 67(4):802-812. PubMed ID: 32202906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.